Cosmos Health Reports 29.7% Revenue Increase in H1 2026

Cosmos Health Inc., a leading health and wellness company, has announced a series of significant achievements for the first half of 2026, marking a transformative period for the firm. The company, which trades on the NASDAQ under the ticker symbol COSM, has set records in revenue and expanded its market presence through strategic partnerships and acquisitions.

In the first half of 2026, Cosmos Health reported a 29.7% increase in revenue compared to the same period in 2025, reaching $36.91 million. This performance, following a 20% growth in FY2025, has set a new record for the company. The strong financials were underpinned by robust growth in each of the company's core segments, including CosmoFarm, Cana, Decahedron, and Sky Premium Life.

Specifically, Q1 2026 saw a 30.7% increase in revenue to $17.93 million, while Q2 2026 saw a 28.8% rise to $18.99 million. The company's operating cash requirements were reduced by more than 30% in the first half of the year, reflecting the combined effects of revenue growth, operating efficiencies, and cost reduction initiatives. This financial discipline has positioned Cosmos Health for greater profitability in the coming years.

A significant milestone for the company was the retirement of an $8 million convertible note 12 months early, which will not be subject to further conversions. This move has simplified the company's capital structure, reducing the risk of dilution. Additionally, Cosmos Health has withdrawn its shelf registration and ATM programs, and removed all structured or floorless warrants, further stabilizing its share count.

The company also repurchased 5.1 million shares for approximately $1.11 million, bringing its total share repurchase activity to $6.1 million since the start of the year. Management has increased its own ownership, with CEO Greg Siokas personally increasing his shareholding by over 11 million shares in 2025 and 2026, bringing his total to 14.6 million shares.

Cosmos Health has also made strides in international expansion and strategic partnerships. In the UK, the company achieved a breakthrough by securing listings for C-Scrub with Tesco, the country's largest retailer, and Superdrug, the second-largest health and beauty retailer. This move has established a significant platform for further product launches and growth. Additionally, C-Scrub has entered hospital and surgical channels following EN 12791 testing, while the veterinary line has been certified under EN 1656 and EN 1657 European standards, opening the door to the $69 billion global animal health market.

Furthermore, the company has secured exclusive distribution agreements in Saudi Arabia and is expanding its presence in the Gulf region. In Dubai, Cosmos Health is exploring additional distribution partnerships, aiming to strengthen its foothold in the region.

Internationally, Cosmos Health is also leveraging non-dilutive financing sources, including a €50 million R&D program advisory agreement with the European Investment Bank (EIB). This financing will support the company's growth and research initiatives, providing additional flexibility and resources.

Analyst coverage has also recognized the company's progress, with Zacks Small-Cap Research initiating coverage with a $4.50 price target, reflecting a significant premium to the current stock price.

In summary, Cosmos Health has demonstrated significant progress in achieving its strategic goals, including record revenue, strategic partnerships, and a robust balance sheet. The company's focus on diversifying its asset base, expanding internationally, and pursuing accretive acquisitions positions it well for continued growth and success in the coming years.